


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

APPOINTMENT OF EXECUTIVE DIRECTORS

The board of directors (the “**Board**”) of The United Laboratories International Holdings Limited (the “**Company**”) is pleased to announce the appointments of Ms. Zou Xian Hong (“**Ms. Zou**”), Ms. Zhu Su Yan (“**Ms. Zhu**”) and Mr. Fang Yuping (“**Mr. Fang**”) as executive directors of the Company (collectively the “**Directors**”) with effect from 1 November 2010.

Ms. Zou Xian Hong, aged 46, is the vice president of the Group. Ms. Zou graduated from Nanjing Medical College of China Pharmaceutical University (中國藥科大學南京藥學院) in 1984 and obtained her Executive Master of Business Administration from Hunan University (湖南大學) in 2005. In June 2010, Ms. Zou obtained a doctorate in management science and engineering at the Business School of Central South University (中南大學商學院). Ms. Zou has over 20 years’ experience in the PRC pharmaceutical industry. Ms. Zou was employed as a teacher at the Hunan Medical Middle School (湖南省醫藥中等專業學校) from 1988 to 1993 prior to joining the Group in 1994. Since joining the Group, she has been responsible for the sales management of the Group. She was responsible for the preparation for the establishment of United Laboratories Chengdu. Ms. Zou has a personal interest in 700,000 shares of the Company.

Ms. Zhu Su Yan, aged 46, is the vice president of the Group. Ms. Zhu graduated from the Medical School of Southeast University in the PRC (中國東南大學醫學院) (formerly known as Nanjing Railway Medical School (南京鐵道醫學院)), with a bachelor of medicine and surgery degree in 1988. She was granted a degree of Executive Master of Business Administration from Business School of Nanjing University (南京大學) in 2005. Ms. Zhu worked in Nanjing Gulou Hospital (南京鼓樓醫院) as a neurosurgeon from 1988 to 1993, and joined Pfizer in 1994. She joined the Group in early 1995 and has served as regional manager of Jiangsu, manager and vice president of national hospital development department and the deputy general manager of the PRC sales team etc. Ms. Zhu has extensive experience in the sales and marketing of pharmaceutical products in the PRC and is principally responsible for the sales and marketing of the Group’s products in the PRC. Ms. Zhu has a personal interest in 300,000 shares of the Company.

Mr. Fang Yuping, aged 47, is the vice president of the Group. Mr. Fang graduated from the Medical School of Southeast University in the PRC (中國東南大學醫學院) (formerly known as Nanjing Railway Medical School (南京鐵道醫學院)), with a bachelor’s degree in medicine in 1986. After graduation, he served as a teaching staff member of the School for eight years. In 1995, Mr. Fang joined the Group and had held a number of positions including the head of China sales office, district manager, regional manager, duty general manager and etc.. He was promoted to vice president of the Group in 2008. Mr. Fang has a personal interest in 100,000 shares of the Company.

As at the date of this announcement, all of the Directors have not been granted any options under the share option scheme of the Company. Save as disclosed herein, (i) the Directors do not have any interest in the shares or underlying shares in the Company within the meaning of Part XV of the Securities and Futures Ordinance; (ii) the Directors do not hold any directorship in other listed public companies or any other major appointments or qualifications in the last three years; and (iii) the Directors were not related to any other directors, senior management, substantial or controlling shareholders of the Company as at the date of this announcement.

Each of the Directors have been appointed from 1 November 2010 and thereafter shall continue for a maximum of three years, pursuant to the service agreements entered into by each of Ms. Zou, Ms. Zhu, Ms. Fang and the Company respectively. At the next annual general meeting of the Company in 2011, pursuant to the Company's articles of association, they shall retire and, subject to their consent and on such terms as the Directors and the Company may agree, offer themselves for re-election. The Directors' subsequent appointment shall also be subject to their re-election following retirement by rotation at any subsequent annual general meeting of the Company in accordance with the articles of association of the Company.

The amount of basic emolument as an executive director for each of the Directors is HK\$1,800,000 per annum and a discretionary monthly incentive bonus of not more than RMB60,000. The Directors' emoluments are determined with reference to their qualifications and experience, their duties and responsibilities with the Company and the prevailing market conditions.

The Directors are not aware of any matters that are required to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules or any other matters that need to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to welcome Ms. Zou, Ms. Zhu and Mr. Fang to join the Board.

By Order of the Board of
**The United Laboratories
International Holdings Limited**
Leung Wing Hon
Company Secretary

Hong Kong, 2 November 2010

As at the date of this announcement, the Board comprises Mr. Choy Kam Lok, Ms. Peng Wei, Mr. Leung Wing Hon, Mr. Tsoi Hoi Shan, Ms. Zou Xian Hong, Ms. Zhu Su Yan and Mr. Fang Yuping as executive directors; Ms. Choy Siu Chit as non-executive director; and Mr. Chong Peng Oon, Mr. Huang Bao Guang and Mr. Song Ming as independent non-executive directors.